HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J announces Q3 results

This article was originally published in The Rose Sheet

Executive Summary

Despite rosy outlook of many economists, Johnson & Johnson CFO and VP-Finance Dominic J. Caruso believes the recession continues to negatively impact U.S. consumer buying patterns and distributor inventory levels in the consumer products segment. During an Oct. 13 third-quarter call, the exec noted that the firm's "core strategy" for overcoming the slump is to "differentiate our products as well as focus on developing strong consumer brands." J&J's U.S. consumer business in the third quarter declined 4.4 percent to $1.69 billion, while the firm's international consumer product revenue was down 1.4 percent, at $2.3 billion; worldwide sales for the business slipped 2.7 percent to $4 billion. Its Aveeno and Dabao skin-care brands and Listerine mouthrinse performed well in Q3, firm notes. Separately, J&J has terminated its agreement with light-based cosmetic treatment developer Palomar Medical Technologies to develop and commercialize devices for reducing the signs of skin aging and reducing or preventing acne. Palomar intends to continue with the development of its home-use laser device to treat periorbital wrinkles, approved by FDA in June, and anticipates launching it in the second half of 2010 (1"The Rose Sheet" June 8, 2009)
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

RS016483

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel